Components:
Method of action:
Treatment option:
Medically reviewed by Militian Inessa Mesropovna, PharmD. Last updated on 12.03.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
symptomatic treatment of rhinitis (runny nose) of allergic and / or infectious-inflammatory etiology,
sinusitis,
evstahiit,
hay fever.
The intranasal route. Before each use, it is necessary to shake the spray bottle vigorously. Before the first application of the nasal spray, it is necessary to calibrate it by pressing the spray head several times.
Adults and children over 6 years of age — 2-3 injections in each nasal passage at intervals of 10-12 hours. The frequency of use can be increased up to 3 times a day in adults. It is not recommended to exceed the specified dose.
hypersensitivity,
atrophic rhinitis,
concomitant use of MAO inhibitors (including a period of 14 days after their withdrawal),
children under 6 years of age.
With caution: coronary artery disease, arrhythmias, chronic heart failure, severe atherosclerosis, hypertension, hyperthyroidism, thyrotoxicosis, diabetes mellitus, chronic renal failure, angle-closure glaucoma, prostatic hyperplasia with clinical symptoms, pregnancy, lactation.
Transient dryness and burning of the nasal mucosa, dry mouth and throat, sneezing, increased blood pressure, increased anxiety, nausea, dizziness, headache, insomnia, palpitations, sleep disorders. With prolonged use — tachyphylaxis, reactive hyperemia and atrophy of the nasal mucosa. Benzalkonium chloride, which is part of the drug, can cause irritation of the mucous membranes of the nasal cavity.
Symptoms: with a significant overdose or accidental ingestion, nausea, vomiting, cyanosis, fever, tachycardia, arrhythmia, increased blood pressure, shortness of breath, mental disorders, central nervous system depression (drowsiness, decreased body temperature, bradycardia, decreased blood pressure, respiratory arrest and coma) are possible.
Treatment: symptomatic, with accidental ingestion-gastric lavage, activated charcoal.
Alpha-given tool for local application. It has a vasoconstrictive effect. Oxymetazoline causes vasoconstriction of the mucous membranes of the nose, paranasal sinuses and Eustachian tube, which leads to a decrease in their edema and the release of nasal breathing in allergic and / or infectious-inflammatory rhinitis (runny nose).
Due to the presence of excipients in the composition of the drug (MCC, sodium carmellose and povidone K29–32) Afrin® nasal spray does not flow out of the nose and does not flow down the throat, because after being injected into the nasal passages, the spray becomes more viscous and is held on the nasal mucosa more effectively than a standard aqueous solution.
According to clinical studies, the drug begins to act within 1 min, and the action lasts up to 12 hours.
When used as a nasal spray, oxymetazoline is practically not detected in the blood plasma.
- Anticongestive agent-alpha-adrenomimetic [Alpha-adrenomimetics]
- Anticongestive agent-alpha-adrenomimetic [Anticongestants]
Slows the absorption of local anesthetic drugs, lengthens their action.
Concomitant use with other vasoconstrictor drugs increases the risk of side effects.
With simultaneous use of MAO inhibitors (including a period of 14 days after their withdrawal) and tricyclic antidepressants-increased blood pressure.
At a temperature not exceeding 25 °C.
Keep out of reach of children.
Shelf life of the drug Afrin®2 года.Do not use after the expiration date indicated on the package.
| Nasal spray | 1 ml |
| active substance: | |
| oxymetazoline hydrochloride | 0.5 mg |
| excipients: disodium edetate dihydrate — 0.3 mg, sodium hydrophosphate — 0.975 mg, sodium dihydrophosphate monohydrate — 5.525 mg, povidone K29–32 — 30 mg, benzalkonium chloride solution 17% — 1.471 mg, macrogol 1450 — 50 mg, benzyl alcohol — 2.5 mg, MCC and sodium carmellose (avicel RC 591) — 30 mg, lemon flavor — 1.5 mg, purified water — q.s. up to 1 ml |
Nasal spray, 0.05%. In a hermetically sealed plastic opaque bottle with a capacity of 23 ml with a fine spray dispenser and a protective cap covered with a shrink wrap to control the first opening with the company's logo, 15 ml. 1 fl. in a cardboard pack.
The safety of the drug in pregnant women and during lactation is not established, so the drug should be prescribed to pregnant or breast-feeding women only if the expected benefit from the use of the drug for the mother exceeds the potential risk to the fetus or infant.
Without a prescription.
With prolonged use (more than one week), the symptoms of nasal congestion may resume. If you need to continue treatment for more than 5 days, you need to consult a doctor.
It is necessary to avoid contact with the drug in the eyes.
Influence on the ability to drive vehicles and work with mechanisms. The drug, when used correctly and in the recommended doses, does not affect driving and working with mechanisms, but if side effects such as dizziness occur, you should refrain from these types of activities.
R01AA05 Oxymetazoline
- H68 Inflammation and blockage of the auditory [Eustachian] tube
- J00 Acute nasopharyngitis [common cold a]
- J01 Acute sinusitis
- J30 Vasomotor and allergic rhinitis
- J30. 1 Allergic rhinitis caused by plant pollen
- J32 Chronic sinusitis
Spray: a white or almost white gel-like suspension with a characteristic citrus smell.
